scholarly journals Cost variation analysis of proton pump inhibitors available in Indian market

2018 ◽  
Vol 7 (8) ◽  
pp. 1626
Author(s):  
Akash Chandra ◽  
Manish Kumar ◽  
Lalit Kumar ◽  
Harihar Dikshit
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Oral Drug ◽  
Medication Cost ◽  
Cost Ratio ◽  
Indian Market ◽  
Cost Variation ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
The Cost

Background: In now days proton pump inhibitors are prescribing more and more by Indian physicians not only in peptic ulcer,gastroesophageal reflux disease, gastritis but also along with non steroidal anti-inflammatory drugs to overcome the side effects as gastric irritation and discomfort by non steroidal anti inflammatory drugs.There are many brands of PPI drugs available in Indian market. Costly drugs can lead to economic burden which results in decreased compliance or even non-compliance. Non –compliance leads to incomplete treatment which tends to increase morbidity.Increase in the patient medication cost was found to associated with decreased adherence to prescription medication.Hence this study was done to assess the cost variation of proton pump inhibitors [PPI] drugs.Methods: The maximum and minimum price of each brand of the drug in INR was noted by using CIMS January to April 2018 edition Drug Today April to June 2018 Vol-1. The cost ratio and the percentage cost variation for individual drug brands was calculated. The cost of 10 tablets/capsules was calculated in case of oral drug and the cost of one 1 vial or ampoule was noted in case of injectable drug. At last the cost ratio and percentage cost variation of various brands was compared.Results: Percentage variation in cost for proton pump inhibitors marketed in india was found to be tablet/capsule Esomeprazole [20mg]:141.17, tablet/capsule Esomeprazole [40mg]:196.29, capsule/tablet Omeprazole[20mg]: 569.53, Tablet/capsule Pantoprazole[40mg]: 248.8, tablet /capsule Rabeprazole[20mg]: 815.78, capsule/tablet Lansoprazole[30mg]: 173.33, Inj. Esomeprazole [40mg] 1 vial: 81.81, Inj. Omeprazole[40mg] 1vial: 47.95, Inj. Pantoprazole[40mg] 1vial: 66.66, Inj.Rabeprazole [20mg] 1vial: 176.625.Conclusions: Tablet Rabeprazole[20mg] shows highest cost ratio and percentage cost variation as 9.15 and 815.78. While Inj. Omeprazole[40mg] 1 vial shows lowest cost ratio and percentage cost variation as 1.47 and 47.95.

scholarly journals Study of the price variation analysis of proton pump inhibitors available in Indian pharmaceutical market

2020 ◽  
Vol 9 (1) ◽  
pp. 226
Author(s):  
Rabi Bhushan ◽  
Anupam Kishore ◽  
Akash Chandra ◽  
Ajay Kumar ◽  
Haribansh Kumar Singh
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Oral Drug ◽  
Medication Cost ◽  
Cost Ratio ◽  
Price Variation ◽  
Cost Variation ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
The Cost

Background: In now day’s proton pump inhibitors are prescribing more and more by Indian physicians not only in peptic ulcer, gastroesophageal reflux disease, gastritis but also along with non-steroidal anti-inflammatory drugs to overcome the side effects as gastric irritation and discomfort by non-steroidal anti-inflammatory drugs. There are many brands of PPI drugs available in Indian market. Costly drugs can lead to economic burden which results in decreased compliance or even non-compliance. Non–compliance leads to incomplete treatment which tends to increase morbidity. Increase in the patient medication cost was found to associated with decreased adherence to prescription medication. Hence this study was done to assess the cost variation of proton pump inhibitors (PPI) drugs.Methods: The maximum and minimum price of each brand of the drug in INR was noted by using Drug Today January to April 2020 edition, Vol-1. The cost ratio and the percentage cost variation for individual drug brands was calculated. The cost of 10 tablets/capsules was calculated in case of oral drug. At last the cost ratio and percentage cost variation of various brands was compared.Results: Percentage variation in cost for proton pump inhibitors marketed in india was found to be tablet/capsule Esomeprazole [20mg]: 297.65, tablet/capsule Esomeprazole [40mg]: 344.41, capsule/tablet Omeprazole [10mg]: 74.51, capsule/tablet Omeprazole [20mg]: 542, Tablet/capsule Pantoprazole [40mg]: 3297.33, tablet/capsule Rabeprazole [10mg]: 1160, tablet/capsule Rabeprazole [20mg]: 1101.05, capsule/tablet Lansoprazole [15mg]: 306.69, capsule/tablet Lansoprazole [30mg]: 336.33,   capsule/tablet Dexlansoprazole [60mg]: 7.69.Conclusions: Capsule Pantoprazole [40mg] shows highest cost ratio and percentage cost variation as 33.97 and 3297.33. While capsule Dexlansoprazole [60mg] shows lowest cost ratio and percentage cost variation as 1.07 and 7.69.

scholarly journals Cost variation analysis of antimalarial drugs available in India

2017 ◽  
Vol 5 (9) ◽  
pp. 4051
Author(s):  
Lalit Kumar ◽  
Jyoti Kumar Dinkar ◽  
Lalit Mohan ◽  
Harihar Dikshit
Keyword(s):  
Antimalarial Drugs ◽  
Fixed Dose ◽  
Oral Drug ◽  
Medication Cost ◽  
Cost Ratio ◽  
Price Variation ◽  
Cost Variation ◽  
Considerable Cost ◽  
The Cost ◽  
Incomplete Treatment

Background: Malaria has been a problem in India for centuries. There are innumerable brands of antimalarial present in the market. Malaria can be extremely fatal if not treated promptly. Costly drugs can lead to economic burden which results in decreased compliance or even non-compliance. Non-compliance leads to incomplete treatment which tends to increase morbidity. Increase in the patient medication cost was found to be associated with decreased adherence to prescription medication. Hence this study was done to assess the cost variation of malaria therapy.Methods: The maximum and minimum price of each brand of the drug in INR was noted by using CIMS January to April 2017 edition and Drug Today January to March 2017, Vol 2. The cost ratio and the percentage cost variation for individual drug brands was calculated. The cost of 10 tablets was calculated in case of oral drug and the cost of 1 ampoule or vial was noted in case of injectable drug. At last the cost ratio and % cost variation of various brands was compared.Results: The analysis of data reflected a considerable cost variation among antimalarial drugs. Artemether injection showed the highest cost ratio and cost variation (cost ratio = 16.96 and % cost variation = 1596). Overall injectable antimalarials showed considerable cost variation as compared to oral antimalarial agents. Chloroquine which is one of the most used antimalarial showed very low values for cost variation and cost ratio.Conclusions: The analysis showed that there is not much significant price variation among oral antimalarial drugs. The maximum variation shown by oral antimalarial was found to be for fixed dose combination of Artemether and Lumefantrine [cost ratio>2 (2.03) and % price variation >100 (103.7)]. But there was significant price variation among injectable antimalarial. Injectable antimalarials are often the choice of drug when dealing with critically ill malaria patients specially when suffering from complicated malaria. So, such significant price variation creates burden on poor patients economically which leads to non-compliance and hence increased morbidity and mortality due to incomplete treatment.

Adherence to proton pump inhibitors or H 2 -receptor antagonists during the use of non-steroidal anti-inflammatory drugs

2003 ◽  
Vol 18 (11-12) ◽  
pp. 1137-1147 ◽  
Author(s):  
M. C. J. M. Sturkenboom ◽  
T. A. Burke ◽  
M. J. D. Tangelder ◽  
J. P. Dieleman ◽  
S. Walton ◽  
...  
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Receptor Antagonists ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

scholarly journals Rational use and cost variation analysis of antitussive-expectorants available in the Indian market: a pharmacoeconomic study

2021 ◽  
Author(s):  
Pramod Kumar Manjhi ◽  
Sunil Kumar Singh ◽  
Chakrapani Kumar ◽  
Akhilesh Kumar Rana
Keyword(s):  
Pharmacoeconomic Study ◽  
Cost Ratio ◽  
Upper Respiratory Tract ◽  
Indian Market ◽  
Rational Use ◽  
Cost Variation ◽  
Upper Respiratory ◽  
The Individual ◽  
Tract Infections ◽  
The Cost

Background: Antitussive-expectorants are among the most frequently prescribed drugs by physicians in clinical practice. Upper respiratory tract infections, such as common cold, acute pharyngitis and acute trachea-bronchitis, are the most common of all communicable diseases and significantly increase OPD burden. This study aimed to assess the rational use, cost ratio, and percentage cost variations in different brands of the commonly prescribed antitussive-expectorants available in the Indian market.Methods: The cost of antitussive-expectorant manufactured by different pharmaceutical companies was obtained by using drug today Jan-April 2021 vol 2. The maximum and minimum price was noted down, cost ratio and percentage cost variation of the individual formulation were analysed.  Results: Analysis of cost ratio and percentage cost variation for each formulation of the antitussive-expectorants drug, syrup (100 ml) chlorpheniramine (2 mg), dextromethorphan (10 mg), phenylephrine (5 mg) combinations show the highest cost ratio and percentage cost variation as 5.30 and 430.25 respectively, and syrup (100 ml) dextromethorphan (10 mg), guaifenesin (100 mg), phenylephrine (25 mg), chlorpheniramine (4 mg) combinations show lowest cost ratio and percentage cost variation as 1.17 and 17.69 respectively.Conclusions: There was a wide variation in the cost of different brands of antitussive-expectorant drugs available in the Indian market. So, clinicians should be aware of rational use and variations in cost to reduce the treatment cost and increase patient compliance.

Sign in / Sign up

Export Citation Format

Share Document